Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STS101 PK and Bioavailability Study
NCT03874832Phase 1Completed
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroergotamine in migraine (5 arms). Primary endpoints: STS101 Dose Selection and DHE Relative Bioavailability. Started Sep 2018; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03874832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874832.